- Total Q3 revenue dropped to $9M compared to $26M in Q3 2025.
- Net loss stood at $128M (EPS -$1.00) versus $135M (EPS -$1.27) in the prior year period.
- Phase 3 PEAK-1 study enrollment expected to complete in next 2-3 months.
Signal #134599 · SEC 8-K
$RCUS SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $RCUS filing catalyst
Why did $RCUS trigger an AI stock catalyst alert?
$RCUS triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: -2.5/10). Headline: Arcus Biosciences Reports Q3 Revenue of $9M Down From $26M, Net Loss at $128M. Key points: - Total Q3 revenue dropped to $9M compared to $26M in Q3 2025. - Net loss stood at $128M (EPS -$1.00) versus $135M (EPS -$1.27) in the prior year period. - Phase 3 PEAK-1 study enrollment expected to complete in next 2-3 months.
How did $RCUS stock react after the SEC filing?
After the SEC 8-K for $RCUS, observed market reaction: T0 price $19.30. Past moves do not guarantee future results.
Where can I get real-time $RCUS SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $RCUS via Telegram and the VIP Web Terminal from €10/month.